Objective The aim of this study was to determine the economic burden from a societal perspective and the health-related quality of life (HRQOL) of patients with haemophilia in Europe. Methods We conducted a cross-sectional study of patients with haemophilia from Bulgaria, France, Germany, Hungary, Italy, Spain Sweden and the UK. Data on demographic characteristics, health resource utilisation, informal care, loss of labour productivity and HRQOL were collected from the questionnaires completed by patients or their caregivers.
Introduction
Haemophilia is a group of X-chromosome-linked hereditary bleeding disorders resulting from a deficiency of factor VIII (in haemophilia A) or IX (in haemophilia B). There is an estimated incidence of 20 per 100,000 male births and this value is independent of race or geographical location.
Figures reported [1] [2] [3] [4] suggest that in high-income Organisation for Economic Co-operation and Development (OECD) countries, the prevalence of haemophilia A is 14 per 100,000 males. However, a further information source is provided by the yearly World Federation of Hemophilia (WFH) survey covering 106 countries, including all of Europe, which estimates a prevalence of 2.6 per 100,000 for haemophilia A and B in the general population [2] . In the countries involved in the BURQOL-RD project, the 2012 WFH Annual Global Survey shows the lowest prevalence to be in Spain, with 6.1 per 100,000 males, and the highest in the UK, with 39.32 per 100,000 males. The WFH data may, however, be overestimated by 30 % with respect to those provided by the literature [4] . Haemophilia usually involves repeated bleeding episodes, which occur mostly in joints and muscles and are associated with a wide range of long-lasting clinical consequences, including loss of range of motion, musculoskeletal disorders and chronic joint disease [5, 6] . Moreover, intracranial haemorrhage (ICH) is a common cause of morbidity and mortality in haemophilic patients: the overall incidence of ICH has been reported to range from 2.2 to 7.5 % [7] . The debilitating joint disease often results in the restriction of patients' activity and reduction in productivity and has a negative impact on their quality of life (QoL) [8] . The disorders are treated by administering the missing coagulation factors by replacement therapy. In the 1960s, the use of plasma-derived factor concentrates made these disorders manageable and made the first significant impact on life expectancy. Recently, recombinant factor concentrates have been introduced that guarantee a high degree of safety after the devastating consequences of widespread HIV infection in patients with haemophilia in the 1980s and 1990s.
A further important innovation in haemophilia treatment in the last 20 years has been the increasing use of prophylactic therapy rather than on-demand replacement therapy, the pioneering example in Sweden in the late 1950s [9] . In general terms, it has been ascertained that ondemand treatment can delay the long-term complications, but it does not prevent them, whereas prophylaxis in patients with severe haemophilia from early childhood prevents such complications [10] [11] [12] .
Moreover, even if prophylaxis requires one or two infusions per week, it is associated with improved quality of life [13] . One-third of adult patients who had access to this treatment in their childhood continue with prophylaxis [14] . The two-thirds who switched to on-demand treatment have suffered an increase in bleeding episodes, although to a lesser extent than patients who never had prophylaxis [15] . Lastly, there is evidence to show that when prophylactic administration of factor concentrates is introduced in adulthood, bleeding events become less frequent, but there is no associated functional improvement [16] . New treatment modalities have greatly extended the life expectancy of patients with haemophilia from 40 years in the 1960s to 60-70 years today [17, 18] , but they have also dramatically increased the cost of the treatment. Haemophilia is an example of how a small portion of the population affected by a rare condition consumes a very large portion of economic resources, thereby increasing the tertiary payers' interest in the disease [19] .
Hence, the scientific literature that has examined economic aspects of treatment in patients with severe haemophilia has focussed mainly on the cost-effectiveness of prophylaxis vs. on-demand therapy [20] [21] [22] [23] or treatment with inhibitors [24] .
Much attention has also been dedicated to the impact of these new treatments and products on the quality of life of patients and their caregivers, revealing a positive outcome. Several studies have tried to identify underlying factors that may be associated with or contribute to lower physical quality of life, including the treatment regimen, disease severity, age, comorbidity and joint status [25] [26] [27] [28] [29] . Given that haemophilia begins at birth, the illness has an impact on the lives of caregivers, although the extent of the impact is largely unknown.
Nevertheless, to our knowledge, less consideration has been given to the economic and the social burden of haemophilia, which has only been estimated in a few European countries (e.g., Belgium, France, Germany) [30] [31] [32] . The BURQOL-RD project therefore provides useful insights into economic and social aspects of haemophilia management in countries not investigated before (Bulgaria, Hungary and Spain), while at the same time providing overall analysis that is probably still lacking, even in countries where previous studies have focussed on access to specific treatment and the related impact on quality of life in particular patient sub-groups [33] .
Our study had two main objectives: first, to estimate the economic costs related to haemophilia from the societal perspective including both direct and labour productivity losses; second, to assess the HRQOL of haemophilia patients and caregivers.
Method Research design and subjects
This was a cross-sectional study of people diagnosed with haemophilia who received inpatient and outpatient care and were living in the community. All patients and caregivers were informed about the study objectives and data confidentiality and were asked to state their understanding of the study conditions and agreement to participate. Cases were recruited thanks to the collaboration of the haemophilia patient associations. The survey was completely anonymous as the patients were contacted by their patient organisation and their answers were sent directly to the researchers without any identification data (name, identification, address, e-mail).
Information and variables of interest
The fieldwork was carried out between September 2011 and April 2013, and the term of the survey was from 3 to 6 months. Questionnaires were administered by e-mail and postal survey through patient organisations. The information sources used in the study were the self-completed questionnaire filled out by patients and their caregivers. Demographic and clinical data were collected from patients previously diagnosed with haemophilia and their caregivers.
Most studies of cost of illness and health-related quality of life (HRQOL) use information gathered at a specific point in time. The questionnaire we used was detailed enough to reduce either exaggeration or underestimation. To estimate resource utilisation, the questionnaire solicited information covering the 6-month period prior to the study (12 months for hospitalisations). Data for the preceding 6 months were extrapolated to the entire year. We considered 6 months to be an appropriate recall period. Patients and caregivers were asked about reductions in working time (temporary and permanent sick leave or early retirement), and these data were used to estimate losses of labour productivity. Also, when care was provided by non-professional caregivers, the informal care time was estimated. Information about QoL was collected from patients with haemophilia through the generic EuroQol 5-domain (EQ-5D) questionnaire [34] .
Costing methodology
We used the prevalence approach to estimate costs from a societal perspective. Disease prevalence takes into account all existing cases during a given year and all healthcare resources used for prevention, treatment and rehabilitation, plus other resources used (formal and informal care) or lost labour productivity within that year as a consequence of the illness considered. Prevalence-based cost-of-illness analysis has the advantage of incorporating measurements of total annual healthcare expenditure, which is particularly relevant for chronic conditions, such as specific rare diseases that require long-term treatment. In this context, a bottom-up costing approach was used to estimate total and average annual costs [35] .
Data on resource utilisation were collected for each patient. The resources used were multiplied by unit costs to estimate the annual cost per patient, with 2012 as the reference year.
Direct healthcare costs
Direct costs were derived from healthcare utilisation. The value of resources used by patients was calculated in terms of the relevant unit costs and the average cost per patient in the sample. Information about the number of hospital admissions was obtained from the questionnaires.
Data for the volume of outpatient care (rehabilitation, medical tests and examinations, visits to health professionals and home medical care) and the number of emergency visits were obtained from the questionnaires. The unit costs that were obtained from different sources and healthcare cost databases (see Supplementary Annex 2) were then multiplied by the number of units of each resource used. Information regarding the medications used by patients with specific rare diseases (RDs) was obtained from the questionnaires. The cost of drugs used by patients was calculated by determining the daily cost for each of the products used (based on the cost of each pack dispensed and the dose used) and then multiplying by duration of use. When no information concerning the number of units per pack was available, we assumed the largest pack-size was dispensed. The costs of prescription drugs used were obtained from the list of approved drugs in the different countries (See Supplementary Annex 2).
Information concerning the use of orthopaedic devices and healthcare-related transportation was obtained from the questionnaires. The costs of orthopaedic devices were obtained from different distribution firms.
Direct non-health care costs
Informal care is defined as the performance of tasks by non-professionals that help maintain or enhance patient independence. Informal services are therefore defined as the group of tasks or care provided by non-professional caregivers, who are often relatives but may also be friends or neighbours. Information about informal care was obtained from the questionnaires, specifically from the items concerning the time spent helping the patient with his or her basic activities of daily living and the time spent helping with necessary instrumental activities of daily living (recall method). As a conservative criterion, and for preventing conjoint production, we have censored the time of care to a maximum of 16 h per day (114 h per week) when the time of care reported exceeded this figure.
The approach used to value the care hours was the proxy good method, which values time as an output. This method values the care provided by the informal caregiver considering that if he/she did not provide these services, their presence would have to be substituted by another person who could provide them [36] . Therefore, we took into consideration the question of how much it would cost to take on said substitution or replacement by hiring a professional caregiver [37] .
Information on formal paid care provided by professional caregivers and other social services was obtained from the questionnaires and comes under the category of social services. Data on unit costs were provided by different sources (See Supplementary Annex 2).
Loss of labour productivity
Data on loss of labour productivity were obtained from physical units converted into monetary units with a human capital-based approach [38] . According to human capital theory, the average earnings (gross wages) of a worker can be considered a good proxy for labour productivity losses. Our calculations were based on average gross wage figures in the National Wage Structure Surveys of the participant countries (See Supplementary Annex 2). Annual losses of labour productivity were estimated for the year 2012.
Patient and caregiver outcomes
Patient and caregiver outcomes were obtained by means of self-administered questionnaires such as the EQ-5D, the Barthel Index and Zarit Burden Interview.
The EQ-5D is a simple generic instrument developed by a multidisciplinary group of researchers [39] . This questionnaire has been validated in many countries in Europe and is commonly used in economic evaluation and health technology assessment. There are five dimensions in the EQ-5D covering the areas of mobility, self-care, everyday activities, pain/discomfort and anxiety/depression. A total of 245 possible health states can be defined in this way. Evaluations of these health states have been reported for the general population [40] . The values or utilities are indicated on a scale on which death has a value of 0 and perfect health a value of 1, with negative values being possible. Country-specific adult value sets were used when available (UK, France, Spain, Germany), otherwise value sets of other countries were used (Danish value set for Sweden, Spanish for Italy, French for Hungary and British for Bulgaria).
The Barthel Index is a widely used tool for the assessment of disability and measures the ability of a person to perform ten basic activities of daily living, providing a quantitative estimate of the subject's degree of dependence [41, 42] . It is easy to apply, has a high degree of reliability and validity, is capable of detecting changes and is easy to interpret. The Barthel Index is recommended as the instrument of choice for measuring physical disability, in both clinical practice and public health research. A score of 91-99 shows mild dependence, 61-90 moderate dependence, 21-60 severe dependence and \20 complete dependence [41] .
Caregivers also completed the Zarit Burden Interview (22-item version), which measures the subjective burden among caregivers. Each item is a statement to which the caregiver is asked to respond to using a 5-point scale, with options ranging from 0 (never) to 4 (nearly always) [43] . The total score ranges from 0 to 88, with scores under 21 corresponding to little or no burden, 21-40 mild-to-moderate burden, 41-60 moderate-to-severe burden and [61 severe burden.
Results
A total of 401 questionnaires were included in the study, of which 339 were collected from patients with haemophilia and 62 from caregivers. Patients with haemophilia included in the study were from Bulgaria, France, Germany, Hungary, Italy, Spain, Sweden and the UK; 60.3 % of the patients (n = 225) were adults (C18 years old) and 94 % male (n = 317). The main characteristics of patients and caregivers are shown in Table 1 . Only 56.4 % of adult patients were married (n = 127) and 76.8 % had a medium/high educational level (secondary schooling and university). Social/economic costs and quality of life in patients... S57
As mentioned above, we assumed a social perspective and have estimated the average annual cost per patient in 2012. The lowest average annual cost per person was reported in Bulgaria (€6660) and the highest in Germany (€194,491). Although not as low as Sweden with the second lowest figure (€8229), France also had a low annual average cost per person (€21,046) considering that recombinant factors and prophylaxis are widely used there (Tables 2, 3 and 4) .
As we look at the three main items of costs from a social perspective, we see that the main driver of costs is direct healthcare in Hungary, Italy, Spain and Germany, while in the other four countries the percentage of direct nonhealthcare costs is higher. However, if we differentiate between children and adults, direct healthcare costs for Bulgarian, French and Swedish children, at 50-70 % of the total, occupy a much higher proportion than they do with adults. The UK sample included two adult patients, preventing a general analysis of haemophilia there (Fig. 1) .
Given the widely debated introduction of recombinant drugs and the increasing use of prophylaxis treatment in the last few years, we focussed on direct healthcare costs and specifically on drugs (Fig. 2) . As we expected, drugs represent nearly 90 % of direct healthcare costs in a majority of the countries analysed. In Bulgaria, France and Sweden, however, healthcare services (visits, tests and hospitalisations) prevail. However, we should stress that in these three countries, expenditure on drugs is higher for children than adults ( Fig. 2 and Tables 3 and 4) .
As one of the main complications in haemophilia is joint disease, reducing or preventing patients' mobility, formal and informal care along with social services can be required, especially in adulthood. Therefore, with this in mind, we analysed in detail the utilisation and related cost of direct non-healthcare services (Fig. 3) ; informal care is the non-healthcare assistance provided to children in all countries, except in France, where there is significant use of social services. As far as adults are concerned, we see that formal care, provided by social services and professional care, is provided to different extents in all countries except Sweden.
Lastly, adults on the proper treatment might have an almost normal working life and currently, in some countries, patients' lost productivity due to sick leave or early retirement is a significant item in overall costs; in Germany, Spain, Italy and Hungary in specific, this item ranges from 2 to 9 % of the average annual cost per person in adults. Moreover, we should highlight the substantial value in absolute terms of German lost productivity, which is €9444.
The results of the EQ-5D, Zarit and Barthel Index are summarised in Table 1 . With regard to the HRQOL of adult patients with haemophilia, the average EQ-5D VAS score was 66.6 (SD 23.1) over 100, with an average EQ-5D index score (TTO tariff) of 0.69 (SD 025). The corresponding average EQ-5D VAS and EQ-5D index scores for caregivers were 75.5 (SD 18.5) and 0.87 (SD 0.15), respectively.
In the disability score, 60 % showed no disability (BI score more than 91), 22 % showed mild-to-moderate dependence (BI score from 90 to 61) and 8 % severe/complete dependence (BI under 60).
Measuring caregiver burden with the Zarit Index produced an overall mean score of 25.3 (SD 13.1), (Table 1) 
Discussion
As mentioned above, the introduction of recombinant factor concentrate and the increasing use of prophylactic treatment have led to an improvement in patients' HRQOL and life expectancy, at the expense of a considerable increase in management costs. Of course, these innovations have different degrees of penetration, depending on the different healthcare resources and strategies from country to country. Moreover, as previously stated, prophylaxis has different outcomes and effectiveness according to a patient's severity, age and number of years on treatment. This means not only that clinicians have different treatment options, but also that policy-makers have to set priorities (i.e., children vs. adults, adults who had access to prophylaxis in their childhood vs. those who did not) and allocate resources consistently.
As we expected, our results demonstrate large differences in the average annual cost per patient in 2012 from country to country, with drugs representing nearly 90 % of direct healthcare costs in a majority of the countries analysed (Hungary, Italy, Spain and Germany). In Bulgaria, France and Sweden, however, healthcare services (visits, tests and hospitalisations) prevail. These cost variations can be attributed to differences in accessibility to replacement therapy across Europe [44] . There is in fact evidence [44, 45] that access to prophylactic treatment by children and adults matches the trend in costs surveyed by the BUR-QOL-RD project, although data from France and Sweden require further investigation. Bulgaria, for instance, provided the prophylactic treatment to 51-75 % of children and 1-25 % of adults with haemophilia in 2012, while in France and Hungary, 76-100 % of children and 25-50 % of adults received prophylaxis. Moreover, Germany implemented the same Hungarian and French standards for children, but increased adult coverage to 51-75 %. Understandably, the focus of the literature on haemophilia is on drug treatments, their cost-effectiveness and, to some extent, the related healthcare services provision. However, the case of Bulgaria shows how non-healthcare assistance might still be an alternative to limited pharmaceutical treatment of patients with poor quality of life.
Moreover, the implementation of a social perspective provides the opportunity to highlight the extent to which good quality of life, achieved mainly through proper treatment, allows these patients not only to limit their need for non-healthcare assistance, but also to contribute to society by returning to active work. In particular, we found that when adults have poor quality of life, in most countries, lost productivity is present as one of the cost items, even though it may carry a different weight according to the country surveyed. These figures confirm that, when treated properly, haemophilia patients can not only have a high quality of life, but can also have an active working life. In this study, the assessment of HRQOL was based on generic questionnaire EQ-5D. The average EQ-5D index score of people who have haemophilia is 0.69 lower than the HRQOL in the general population [39] . The distribution of the HRQOL score did not differ substantially from one country to another (Table 1) . People with haemophilia rate their health status as impaired not only physically, but also in terms of mental health. Many factors may influence the HRQOL score. The characteristics of the disorder and its treatment (severity of haemophilia, number of bleeding events, inhibitor status as well as type of treatment, i.e., prophylactic versus on-demand) are important predictors and are also dependent on the healthcare system and specific characteristics of a given country [46] .
Although the BURQOL-RD research provides useful information and estimations on the social and economic burden of haemophiliac patients in each of the surveyed countries, we were unable to estimate ''cost of illness''. This was because we did not know the proportion of patients with severe illness in each country and so we could not survey costs according to this distinction. Therefore, even if we knew the ratio of severe patients in some countries (e.g., the UK, Sweden), we would not be able to distinguish the costs for patients with severe haemophilia from those with mild disease and the related average annual cost, which would be necessary to estimate the cost of illness in a particular country [47, 48] .
Conclusion
We have shown that there is a substantial economic burden and impaired HRQOL associated with haemophilia, making cost-of-illness and HRQOL studies important in this disease. The future of this disease is likely to change with the development of innovative treatments, such as long-acting clotting agents and gene therapy, and the availability of biosimilars [49] . In addition, the introduction of these treatments will most likely impact future costs related to haemophilia. Our study is in line with the growing interest of authorities in rare diseases, such as haemophilia, with respect to national management strategies in Europe [50] .
